MuriGenics
Private Company
Total funding raised: $3M
Overview
MuriGenics operates as a preclinical-stage service provider, not a traditional drug development biotech. It offers specialized contract research services to pharmaceutical and biotechnology companies, leveraging over 50 years of collective scientific experience from its team. The company's business model is based on delivering validated, on-time preclinical study results, with growth driven by repeat customers. Its focus areas include developing integrated assay protocols to maximize data output while minimizing resource use for clients.
Technology Platform
Integrated preclinical service platform specializing in protocol development that combines in-vivo and in-vitro assays to maximize data yield. Capabilities include animal models, in-vitro testing, and histology services.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
MuriGenics competes in the fragmented preclinical CRO market, facing competition from global giants (e.g., Charles River Laboratories, Labcorp) and numerous small, niche providers. Its differentiation is based on a personalized service model, integrated assay design, and deep scientific expertise from its leadership team, targeting clients who prefer a collaborative partnership over a transactional vendor relationship.